Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, metastatic, non-squamous, non-small cell lung cancer ...

New UAB research uncovers how NFAT helps uterine NK cells support early placenta development, shedding light on pregnancy health and the roots of complications like preeclampsia.

March 11, 2026. Gesynta Pharma AB today announced that the first patient has been dosed in its Phase 2 clinical proof-of-concept trial (NOVA) of vipoglanstat, a novel non-hormonal, non-opioid drug ...

Gesynta Pharma AB today announced that the first patient has been dosed in its Phase 2 clinical proof-of-concept trial (NOVA) of vipoglanstat, a novel ...